Baudax Bio (BXRX) President & CEO Gerri Henwood - C-Suite Interview Series

Recorded February 23, 2022. Noble Capital Markets Senior Research Analyst Gregory Aurand sits down with Baudax Bio President & CEO Gerri Henwood for this exclusive interview. Topics covered include:

An overview of Baudax Bio and their product profile

How are Anjeso commercial activities progressing?  Has Covid shifted the strategy?

What proposed CDC opioid guidelines mean for Baudax

Long term opportunities for neuromuscular blocking agents

Does the recent stock split cure the Nasdaq difficiency?

What will get the stock moving in the right direction going forward?

 

Research, News, and Market Data on Baudax Bio: https://channelchek.com/company/BXRX

Baudax Bio is a pharmaceutical company focused on commercializing and developing innovative products for acute care settings. ANJESO is the first and only 24-hour, intravenous (IV) COX-2 preferential non-steroidal anti-inflammatory (NSAID) for the management of moderate to severe pain. In addition to ANJESO, Baudax Bio has a pipeline of other innovative pharmaceutical assets including two novel neuromuscular blocking agents (NMBs) and a proprietary chemical reversal agent specific to these NMBs. For more information, please visit www.baudaxbio.com.